The life sciences firm Draper & Dash has been working with healthcare providers across the globe since 2015 to streamline processes and deliver increasingly positive health outcomes. Using artificial intelligence and machine learning, the predictive artificial intelligence specialist works with clients such as the NHS to isolate and analyse data from their existing healthcare systems. By implementing predictive analytics, the business is then able to offer a service that goes beyond recognising and reporting trends: it is able to identify health patterns before they actually emerge.

Draper & Dash will use the loan to expand its operations into the pharmaceutical market, in recognition that its predictive analytics capabilities can have a significant impact on patient safety, efficacy and overall real-world evidence provision. The firm, which has already won several global master service agreements with major international pharmaceutical companies, will increase its investment in research, also recruiting life sciences specialists and development experts to further accelerate the company’s growth.

Predictive capabilities improve healthcare outcomes

“As an established data science business in the health sector, we have commercial partnerships in place with a number of health systems to access multiple de-identified sources of data, with full patient data protection in place. This means we can use our technology to identify disease patterns and profiles; in turn, this accelerates drug development and time to market,” says Chris Williams, chief financial officer at Draper & Dash.

“Draper & Dash has identified a new market to add to a proven core business,” says Kerry Barron, senior investment manager at BOOST&Co. “This deal is an excellent example of a business recognising that it could flex and expand into a new market and using growth funding to do it. We are thrilled to support the team and look forward to witnessing their success in the coming months and years.”


Back to all investments